2 results
Approved WMOCompleted
PHASE IIPrimary ObjectiveThe primary objective of the Phase II portion of the study is to estimate the efficacy as measured by radiographic progression-free survival of IPATASERTIB (GDC-0068) (dosed at either 400 mg or 200 mg daily) + abiraterone…
Not approvedWill not start
The primary objective is to investigate if thermal ablation of breast tumors less than 2cm with < 25% DCIS is effective in terms of the number of tumors in which complete ablation is found on pathology result.